SGMT · Sagimet Biosciences Inc.

Track SGMT — free

$10.18 -0.40 (-3.78%) At close · Aug 20

Market Cap

$635.88M

62.16M

Up next

Next earnings call

Mar 26, 2027 Est · unconfirmed · in 31 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 11, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +52%

above

Price vs 50-day avg +30%

above

RSI (14) 69

neutral

MACD trend Positive

52-week position 93%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +45%

trailing

6-month return +78%

trailing

YTD return +72%

this year

Relative strength +67%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $8 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+39% holders QoQ · +57 funds added

Insider flow Distributing

Net -$578.9K over 90 days · 100% sells

Short interest Rising

18.65% of float · ▲ +19.0% MoM · 16.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

122 holders — near 3-yr high, broad support

Squeeze score 80

high risk · 0–100

Fundamentals

Fair

EPS growth −9%

Y/Y

Balance sheet $35.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 86%

annualized · 1-yr

Max drawdown −50%

past year

ATR 5.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+52% Bullish

Price vs 50-day avg

+30% Bullish

RSI (14)

69 Neutral

MACD trend

Positive Bullish

52-week position

93% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $8 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+39% holders QoQ · +57 funds added

Insider flow Distributing

Net -$578.9K over 90 days · 100% sells

Short interest Rising

18.65% of float · ▲ +19.0% MoM · 16.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

122 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $10 · 93% Range high $11

vs 200-day avg +52% vs 50-day avg +30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash, cash equivalents and marketable securities	$257.6M	as of 6/30/2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
SGMT Sagimet Biosciences Inc. this stock	$635.88M	+72.0%	—	—	18.7%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

122

% held: 83.2%
Net QoQ: +38.0M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

11.6M

Days to cover: 16.3d
Change: +1.9M sh

View

Short Volume

Short vol %

46%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $358
As of: Jul 28, 2026

View

Off-Exchange

Off-exchange %

46.1%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$578.9K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$2.0M

Net income (FY): $-51.0M
EPS diluted: $-1.58

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 13, 2026
This year: 17

View

Proposed Sales

Value

$3.3M

Shares: 351.0K
Filed: Aug 14, 2026

View

Exempt Offerings

Offering

$80.0M

Filed: Jan 5, 2021

View

Earnings & Events

Earnings Calls

Last call

Aug 11, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
SGMT	+9.7%	+45.2%	+78.3%	+43.2%	+72.0%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+11.7%	+41.9%	+67.1%	+41.1%	+60.1%

Key facts CIK 1400118 CUSIP 786700104 13F (30d) 121 filings 119 filers Visit website Investor relations

SGMT · Sagimet Biosciences Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance